Objective-Calcific aortic valve (AV) disease, characterized by AV sclerosis and calcification, is a major cause of death in the aging population; however, there are no effective medical therapies other than valve replacement. AV calcification preferentially occurs on the fibrosa side, exposed to disturbed flow (d-flow), whereas the ventricularis side exposed to predominantly stable flow remains protected by unclear mechanisms. Here, we tested the role of novel flow-sensitive UBE2C (ubiquitin E2 ligase C) and microRNA-483-3p (miR-483) in flow-dependent AV endothelial function and AV calcification. Approach and Results-Human AV endothelial cells and fresh porcine AV leaflets were exposed to stable flow or d-flow.
C alcific aortic valve disease (CAVD), characterized by aortic valve (AV) stenosis and insufficiency (regurgitation), is a major cause of cardiac-related deaths worldwide, especially in the aging population of advanced countries. 1, 2 Once developed, it is primarily treated through AV repair or replacement by surgical or transcatheter methods 3, 4 ; however, there are currently no pharmacological treatment options available. CAVD is no longer considered a passive degenerative disease, but it is actively regulated via cellular and molecular pathways that lead to sclerosis (thickening and fibrosis) and calcific lesions. [5] [6] [7] [8] [9] [10] [11] AVs are a tri-layered structure composed of the fibrosa (in the aortic side), spongiosa (the middle layer), and ventricularis (facing the left ventricle). Endothelial cells (ECs), valve interstitial cells (VICs), and leukocytes are key cell types found in the AV and are actively regulated by genetic, biological pathways, and mechanical forces (eg, shear and stretch). 8, 12 Multiple pathogenic processes leading to CAVD have been identified: endothelial dysfunction, inflammation, endothelial-mesenchymal-transition (EndMT), angiogenesis, apoptosis, extracellular matrix remodeling, fibrosis, and osteogenesis lead to sclerosis and calcification. 12 Endothelial dysfunction and inflammation are early events, which in turn lead to phenotypic switching of quiescent VICs to activated VICs and osteogenic VICs, resulting in AV sclerosis and calcification. 7, [12] [13] [14] Factors produced in AV ECs in response to various stimuli, including shear stress, which promote inflammation, Interestingly, AV disease occurs in a side-specific manner. The fibrosa side is exposed to disturbed flow (d-flow), characterized by low magnitude and oscillatory shear stress (oscillatory shear index ≈>0.25), 19 and is preferentially calcified. In contrast, the ventricularis side is exposed mostly to stable flow (s-flow), characterized by high magnitude, unidirectional, and pulsatile shear stress (oscillatory shear index ≈<0.1), 19 and is often protected from calcification. 1, 6 The side-specific AV calcification is hypothesized to be due to endothelial dysfunction in response to d-flow in the fibrosa, whereas anti-inflammatory and anti-calcific responses prevail in the ventricularis side exposed to a more favorable flow condition. 20, 21 AV leaflets respond to various flow conditions mimicking d-flow and s-flow in a manner consistent to the in vivo conditions. For example, exposure of porcine AV (PAV) leaflets ex vivo to d-flow increases matrix proteinase activities, 22 stimulates extracellular matrix remodeling, 23 and increases AV calcification 23 in comparison to the s-flow. In the case of arteries, d-flow leads to atherosclerosis by regulating flow-sensitive genes and proteins in ECs, which leads to endothelial dysfunction and proatherogenic pathways. [24] [25] [26] However, it is less clear which flow-sensitive genes and proteins in the AV regulate CAVD.
To identify flow-sensitive and side-specific genes, we previously conducted gene (mRNA) and microRNA (miRNA) microarray studies using human AV ECs exposed to unidirectional laminar flow (s-flow) or oscillating flow (d-flow) as well as in PAV leaflets. 23, 27, 28 The roles of these flow-sensitive miRNAs in AV biology and disease are beginning to emerge but are far from clear. Recently, we showed that miR-214 and miR-181b expression is upregulated by d-flow in human AV ECs (HAVECs) and in the PAV fibrosa. 23 , 28 We further showed that exposure of PAV leaflets to d-flow increased miR-214, which regulated TGF-β expression with moderate effect on collagen production but no effect on AV calcification. 23 We also found that d-flow-induced miR-181b regulated matrix metalloproteinase activity in part by targeting the tissue inhibitor of metalloproteinases-3 in HAVECs, but its effect on AV calcification is still unclear. 28 In this study, we investigated miR-483 because our gene array data indicated that it might be a flow-sensitive miRNA in HAVECs. Recently, miR-483 has been shown to target the connective tissue growth factor, which mediates EndMT in human umbilical vein ECs. 29 In another study using vascular smooth muscle cells and heart tissue samples, angiotensin II reduced expression of miR-483, which was shown to target 4 members of the renin-angiotensin system: angiotensinogen, ACE (angiotensin-converting enzyme)-1, ACE-2, and type II angiotensin receptor 30 ; however, the role of miR-483 in HAVEC biology and CAVD is still unknown.
Here, we found that UBE2C is a major target of miR-483.
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UBE2C, also known as UBCH10, is an E2 ubiquitin conjugating enzyme. Although overexpression of UBE2C is well documented in various cancer cells, [32] [33] [34] [35] [36] its role in endothelial function and CAVD is yet to be determined. Ubiquitination is upregulated in calcified valves, 37 but its underlying mechanisms and whether it plays any role in AV calcification or endothelial function are unknown. Interestingly, HIF-1α (hypoxia-inducible factor-1α) expression, which is controlled by pVHL (Von Hippel-Lindau protein), [38] [39] [40] [41] is upregulated by d-flow conditions in vascular ECs and atherosclerotic conditions. 42 UBE2C is a member of the APC/C (anaphase promoting complex/cyclosome), which is also known to bind to pVHL. 43 Therefore, we hypothesized that UBE2C would regulate the HIF-1α pathway by controlling pVHL.
Here, we show the novel mechanism by which the miR-483 target, UBE2C, regulates the pVHL and HIF-1α pathway, leading to endothelial inflammation, EndMT, and subsequent AV calcification. We also show evidence suggesting that miR-483 mimic and HIF-1α inhibitors may serve as potential therapeutics to reduce CAVD.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Cell Culture and In Vitro Flow System
HAVECs were isolated from noncalcified AVs obtained from transplant recipient hearts (n=6) following the Institutional Review Board-approved protocol at Emory University as we have previously 27 Patient characteristics used for HAVEC isolations as well as the detailed cell purity characterizations were described in detail in our previous publication. 44 For the majority of our flow experiments, we exposed confluent cells to steady unidirectional flow (s-flow, 20 dyn/cm 2 ) or bidirectional oscillatory flow (d-flow, ±5 dyn/cm 2 at 1 Hz) to mimic the ventricularis-and fibrosa-side flow, respectively, using the cone-and-plate viscometer for 24-hour experiments, as we reported. 45, 46 In brief, a cone controlled by a motor is placed in a standard 10 cm tissue culture dish containing confluent HAVEC monolayer. The cone was rotated unidirectionally or bidirectionally at different velocities to generate s-flow and d-flow conditions, respectively. Under these conditions, s-flow induces anti-inflammatory KLF2 (Krüppel-like factor 2) expression and d-flow generates inflammatory signaling at levels like those observed in vivo. 27 For some studies, we used the Ibidi flow channel system (Ibidi, Munich, Germany) to expose HAVECs to >72 hours of shear to maintain sterility throughout the chronic studies that require media change. The Ibidi shear system was set up per the company's instructions, and proprietary software was used to control the level of shear applied to cells by controlling total media flow rate through the channels of known dimensions.
Human embryonic kidney (HEK) cells were purchased from ATCC (CRL-1573) and cultured in DMEM (VWR Scientific 45000-332; 4.6 g/L glucose), 10% FBS (Atlanta Biologicals S11550), 1% L-Glutamine (Thermo Fisher Scientific 25030-081), and 1% Penicillin Streptomycin (Life Technologies 15140122).
PAV Tissue Harvest and Ex Vivo Shear Experiment
Hearts were obtained from healthy, female, nonpregnant pigs (aged 6-12 months) immediately after slaughter from a local abattoir (Holifield Farms, Covington, GA). The abattoir handles nearly exclusively female pigs because of an undesirable meat quality of male pigs for human consumption. The AV leaflets were immediately excised and thoroughly rinsed in sterile, nuclease-free Hanks' balanced salt solution (HBSS) at 4°C. These excised leaflets were then placed in either RNAlater (Thermo Fisher Scientific AM7020; for generation of miRNA samples) or HBSS at 4°C (VWR Scientific 45000-462; therapeutic studies). Valves were placed on ice and transported back to the laboratory. Upon arrival in the laboratory, dissected AVs were transferred to sterile HBSS at 4°C under the sterile laminar flow hood and processed accordingly. Endothelial enriched RNA was obtained as previously described. 27 For static calcification studies, leaflets were placed under osteogenic media. Osteogenic media is composed of regular DMEM (VWR Scientific 45000-332) supplemented with 1 mmol/L glycerophosphate (Sigma Aldrich G9422), 10 μmol/L dexamethasone (Sigma Aldrich D4902), 3.8 mmol/L PO 4 3− (Fisher Scientific S374), and 1 ng/mL transforming growth factor (TGF-β 1, Sigma Aldrich t5050). This media has been shown to induce accelerated calcification in PAVs. 47 Tissues were transfected, and media were changed at the start of the experiment and every 3 days for up to 14 days. To study the effect of flow on PAV leaflets, the cone-and-plate bioreactor was used as we previously described. 23, 48, 49 AV leaflets were exposed to the fibrosa or ventricularis flow 48, 49 in the osteogenic media for 7 days (Figure XIVA in the online-only Data Supplement). Media were changed every 3 days, and the entire setup was placed in a 5% CO 2 incubator at 37°C.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated using miRNeasy Mini Kit (Qiagen 217004) and reverse transcribed for use in a 2-step quantitative reversetranscribed polymerase chain reaction (PCR) using a qRT-PCR kits (Applied Biosystems 4368814). For measurement of mRNA targets, quantitative real-time PCR (qPCR) was performed on selected genes using VeriQuest Fast SYBR QPCR Master Mix (Affymetrix 75690) with custom designed primers using 18S as house-keeping control. The PCR conditions were 2 minutes at 50°C, 5 minutes at 95°C, followed by 40 cycles of 95°C for 4 s and 60°C for 30 s. Fold changes between s-flow and d-flow were determined for all targets using the ΔΔCt method.
Mature miRNA assays were performed using miRNA quantification and were performed by SYBR green qPCR assay using miScript reverse transcription kit (Qiagen 218161) according to the manufacturer's instructions. qPCR was performed using VeriQuest Fast SYBR QPCR Master Mix (Affymetrix 75690) with miScript universal primer (Qiagen MS00033740) and the miRNA-specific forward primers; and relative fold change was calculated. The specific mature primers were purchased from Qiagen. The amplification profile was denaturation at 95°C, 15 minutes, followed by 40 cycles of 94°C, 15 s; 55°C, 30 s; and 70°C, 30 s.
Monocyte Adhesion Assay
Monocyte binding was determined using THP-1 monocytes (ATCC TIB-202). In brief, THP-1 cells (1.5×10 5 cells/mL) were labeled with a fluorescent dye 2-,7-bis(carboxyethyl)-5 (6)-carboxyfluorescein-AM (Thermo Fisher Scientific B1150; 1 mg/mL) in serum-free RPMI medium (Thermo Fisher Scientific 11875093) for 45 minutes at 37°C. After exposure to flow or transfection treatments, the ECs were washed in RPMI medium before adding 2-,7-bis(carboxyethyl)-5 (6)-carboxyfluorescein-AM-loaded THP-1 cells. After a 30-minute incubation at 37°C under no-flow conditions, unbound monocytes were removed by washing the endothelial dishes 5× with HBSS and cells with bound monocytes were fixed with 4% Paraformaldehyde (Sigma Aldrich 47608) for 10 minutes. Bound monocytes were quantified by counting the cells under a fluorescent microscope.
Immunofluorescent Staining of Human AV Tissues
Human AVs were obtained immediately after valve replacement surgeries in 16 patients at Emory University Hospital Midtown according to the IRB-approved study at Emory University with written informed consent. We previously reported the detailed patient demographics of this cohort used for this study. 44 In brief, 15 patients had trileaflet valves, whereas 1 patient had a bicuspid AV. Average age was 66 years old with 44% female, 12.5% patients with diabetes mellitus, 38% dyslipidemic patients, and 75% hypertensive patients. Immediately after harvesting, the AVs were photographed, washed in ice-cold PBS, and cusps were individually snap-frozen in optimal cutting temperature compound (Tissue-Tek 23-730-571). Valves were then sectioned (8 µm) in the radial direction to include the base and free edge (tip), stored at −80°C and used for immunohistochemical staining studies.
Staining was performed as we have described previously, 44 using specific antibody against UBE2C (Protein Tech 12134-2-AP), pVHL (Thermo Fisher Scientific PA5-27322), HIF-1α (Bethyl Laboratories A300-286A), CD31 (Abcam, ab9498), TWIST1 (EMD Millipore ABD29), RUNX2 (Santa Cruz Biotechnology SC10758), or VCAM1 (vascular cell adhesion molecule 1; Abcam, ab134047) and appropriate secondary antibody conjugated to fluorophore at Alexa 488 or Alexa 568 (Life Technologies A11004 or A11011). Hoechst 33342 (Life Technologies H3570) was used to stain nuclei. All measurements were performed using ImageJ (NIH) and were represented as staining intensity normalized to DAPI intensity.
Transient Transfection With Oligonucleotides or Plasmid
For the functional tests of miR-483 in vitro and ex vivo, cells or PAV leaflets were transiently transfected with miRNA-483 mimic (Exiqon 472350-001), nontargeting miR-mimic control (Qiagen YM00479902-ADA), anti-miR-483 (Exiqon 4100225), mismatched anti-miR control (Exiqon 4101427-102), siRNA control (Dharmacon D-001810-10-20), siRNA UBE2C (Dharmacon L-004693-00-0005), siRNA pVHL (Dharmacon L-003936-00-0005), or siRNA HIF-1α (Exiqon 500100) using Oligofectamine (Invitrogen 12252011), as we described previously. 50 For static conditions, cells were lysed 48 hours after the transfection for RNA or protein assays. For flow experiments using the cone-and-plate system, HAVECs were first transfected for 24 hours, then exposed to flow for another 24 hours. For flow experiments using Ibidi system that requires a longer time (≈72 hours) to align, transfected HAVECs were exposed to flow for another 72 hours. For ex vivo studies, AV leaflets were transfected every 72 hours when the tissues received fresh media. After flow exposure, cells were lysed for RNA or protein assays.
For plasmid transfections, Lipofectamine 3000 (Thermo Fisher Scientific 15338030) was used as transfection reagent following manufacturers' protocol. The plasmids used were as follows: pCMV6-UBE2C Myc-DDK-tagged (Origene technologies, RC208741), RpCMV-DsRed-Express2 (RFP, SnapGene pIRES2 DsRed-Express 2), pRc-CMV-HA-pVHL-WT, HA-pVHL-RRR, HA-pVHL-KRR, HA-pVHL-RKR, and HA-pVHL-RRK.
51,52

Immunoprecipitation Studies
For pVHL or ubiquitin immunoprecipitations, 25 μL of goat-antirabbit IgG (New England Biolabs, S1432S) or goat-anti-mouse IgG (New England Biolabs, S1431S) magnetic beads was preincubated (2 hours at RT) with 5 μg of anti-VHL antibody (Thermo Fisher Scientific PA5-27322) or an anti-total ubiquitin antibody (Abcam ab128424). Cells were lysed using an IP lysis buffer (Thermo Fisher Scientific 87787) and added to the magnetic beads overnight at 4°C. The magnetic beads were then washed 5× with a Tris-EDTA buffer to remove nonbound proteins, and the bound proteins were separated from the beads by adding SDS buffer and boiling the protein for 5 minutes. Immunoprecipitated samples were subjected to standard SDS-PAGE and Western blot. For HA-tag immunoprecitations, an anti-HA immunoprecipitation kit (Sigma-Aldrich IP0010) was used per the manufacturer's instruction. Immunoprecipitated samples were subjected to SDS-PAGE and Western blot as described above.
Cell Proliferation
After treatment, cells were fixed with 4% formaldehyde and stained for KI-67 (Abcam ab15580) and DAPI. Cells were quantified using ImageJ for both KI-67-positive cells and normalized to number of DAPI cells.
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Cell Cycle
After treatment, cells were detached from culture dish using trypsin, washed twice in HBSS with 2% FBS (centrifuged at 1000g for 5 minutes), and fixed with 70% ice-cold ethanol added dropwise while gently vortexing. Cells were then washed twice with HBSS (centrifuged at 1250g for 5 minutes). Finally, a solution of PI stain (50 μg/mL; Invitrogen P1304MP) with RNAse A (0.5 μg/mL; Qiagen 19101) was added to the cells for 15 minutes before analysis using flow cytometry. Data were analyzed using FlowJo software. 53 
Apoptosis Tunel Staining
After treatment, cells were fixed with 4% formaldehyde and apoptosis was quantified using an in situ Cell Death Detection Kit from Roche (Roche cat. no. 11684795910) using the provided protocol. Cells were quantified microscopically using ImageJ. 49 
Cell Migration
After treatment, cell monolayers were scratched with a 200-μL pipette tip. The monolayer was washed once, and the medium was replaced with 2% FBS media. Cells were quantified every 2 hours, and the cell velocity was calculated using ImageJ. 54 
Preparation of Whole-Cell Lysate and Immunoblotting
After treatment, cells were washed 3× with ice-cold HBSS and lysed with RIPA buffer (Boston Bioproducts BP-421). The protein content of each sample was determined by Pierce BCA protein assay. Aliquots of cell lysate were resolved by size on 10% to 12% SDSpolyacrylamide gels and subsequently transferred to a polyvinylidene difluoride membrane (Millipore). The membrane was incubated with the following antibodies: UBE2C (Protein Tech 12134-2-AP), Ubiquitin (Santa Cruz Technologies, sc-8017), HA-tag (SigmaAldrich 11867423001), pVHL (Thermo Fisher Scientific PA5-27322), GAPDH (Santa Cruz Biotechnology, sc-25778), or β-Actin (Sigma Aldrich, A5316) overnight at 4°C at the concentration recommended by the manufacturer, followed by secondary antibody (Santa Cruz Biotechnology, 1:5000) for 1 hour at RT. Protein expression was detected by a chemiluminescence method.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software. All of the n numbers represent biological replicates. When technical replicates or triplicates were performed, those values were averaged and used as 1 biological data point. Error bars depict the SE of the means. Initially, the data sets were analyzed for normality using the Shapiro-Wilk test (P<0.05) and equal variance using the F test (P>0.05). Data that followed a normal distribution and possessed equal variance were analyzed using 2-tailed Student t test or 1-way ANOVA, where appropriate with Bonferroni post hoc test as needed. In the case where the data showed unequal variances, an unpaired t test with Welch correction was performed or Brown-Forsythe and Welch ANOVA for multiple comparisons. In the case where the data failed the Shapiro-Wilk test (P>0.05), a nonparametric MannWhitney U test was conducted for pairwise comparisons or the Kruskal-Wallis for multiple groups was performed. For human AV staining studies, we conducted 1 sample t test if the data followed a normal distribution else a Wilcoxon signed-rank test was performed. A P value <0.05 was considered statistically significant.
Results miR-483 Expression Is Flow Sensitive and Side Specific, and It Inhibits Flow-Induced EndMT and Endothelial Inflammation
In our previous microRNA array study using HAVECs, miR-483 appeared to be a flow-sensitive miRNA, 27 but its function was unknown. To confirm this, we validated the flow sensitivity of miR-483 by qPCR in HAVECs. Subjecting HAVECs to d-flow conditions for 24 hours decreased miR-483 expression by 63% compared with the s-flow condition ( Figure 1A ). In addition, we found that miR-483 level in static condition was similar to the d-flow conditions ( Figure IA in the onlineonly Data Supplement). To determine whether miR-483 is expressed in a side-specific manner in AVs, endothelialenriched RNAs were collected from healthy PAVs and miR-483 expression was quantified by qPCR. Endothelial purity levels of these RNA preparations were assessed by measuring markers of macrophages (CD11b), ECs (PECAM1), and VICs (α-SMA) by qPCR. Consistent to our previous report where we developed our endothelial-enriched RNA preparation method, 23 our endothelial-enriched RNA preparations used in this study showed an abundant level of PECAM1, whereas the levels of CD11b and α-SMA were barely detectable ( Figure  II in the online-only Data Supplement). The level of miR-483 was 45% lower in the fibrosa side (naturally exposed to d-flow conditions) compared with the ventricularis side (naturally exposed to pulsatile, s-flow conditions; Figure 1B Figure 1C ), which was significantly reduced by treatment with miR-483-mimic in HAVECs. We also tested other markers of EndMT such as CALPONIN, α-SMA, and VE-CADHERIN and even though they showed a trend they were not significant, so we decided not to study them further. In contrast, anti-miR-483 treatment dramatically increased EndMT markers under the s-flow condition in HAVECs (Figure 1D ), suggesting a major role of miR-483 in flow-sensitive EndMT.
Next, we tested whether miR-483 regulates OS-induced endothelial inflammation as determined by monocyte adhesion and expression of proinflammatory marker genes (IL6, ICAM1, and VCAM1; Figure 1E On the other hand, miR-483 mimic showed no effect on apoptosis, whereas antimiR-483 induced apoptosis by 2-fold compared with control ( Figure IVB in the online-only Data Supplement). Last, miR-483 modulation showed no significant effect on cell migration or cell cycle ( Figure IVC and IVD in the online-only Data Supplement). Together, these results showed that reduction in miR-483 level under d-flow condition leads to endothelial inflammation and EndMT, which are well known to be critical for CAVD pathogenesis. [6] [7] [8] [9] [10] [11] 55 
UBE2C Is a Flow-Sensitive and Side-Specific Target of miR-483 in HAVECs and in Human AVs
To determine the mechanisms by which miR-483 mediates flow-dependent effects on HAVEC function, we identified potential targets of miR-483. To this end, we conducted an in silico analysis comparing the predicted targets of miR-483 (950 predicted genes by the miRWalk and miRTarBase databases) with d-flow-induced genes (239 genes) from our previous HAVEC transcriptome array study 27 ( Figure VA in the online-only Data Supplement). This in silico analysis revealed 9 genes that were predicted gene targets of miR-483 and flow-sensitive genes in our HAVEC transcriptome microarray: ABCB9, ASH2L, DHX33, GADD45B, PSAT1, PSEN2, TMEM88, TOMM20, and UBE2C ( Figure VB in the onlineonly Data Supplement). To determine whether they are also flow-sensitive, HAVECs were exposed to s-flow or d-flow for 24 hours and the expression of these 9 genes was tested by qPCR. This study indicated that d-flow increased 6 of these 9 genes (Figure VB in the online-only Data Supplement). We next determined which of these 6 flow-sensitive genes were significantly regulated by miR-483 using the miR-483-mimic or anti-miR-483. The results showed that ASH2L, UBE2C, and PSAT1 were consistently regulated by the miR-483 modifications in static HAVECs ( Figure VC and VB in the online-only Data Supplement). We further validated if the flow-sensitive expressions of ASH2L, UBE2C, and PSAT1 were mediated by miR-483 after treatment of HAVECs with miR-483 mimic under the d-flow condition or anti-miR-483 under the s-flow condition. ASH2L and UBE2C were regulated by miR-483 under flow conditions, but PSAT1 was not ( Figure VE and VF in the online-only Data Supplement). These results demonstrate that ASH2L and UBE2C are flow-sensitive targets of miR-483. Interestingly, knockdown of UBE2C alone dramatically prevented OS-induced endothelial inflammation (as discussed below in Figure 2H ), demonstrating its dominant role. Although both UBE2C and ASH2L are likely to play major roles in CAVD, they are involved in potentially 2 very complex and different pathways (UBE2C on ubiquitin-dependent pathways and ASH2L on epigenetic regulation through histone modifications) and studying both simultaneously would interfere with focused studies; therefore, we decided to concentrate on UBE2C.
At the protein level, d-flow exposure significantly increased UBE2C expression compared with the s-flow condition in HAVECs (Figure 2A and 2B ). In addition, the d-flow-induced increase in UBE2C expression was significantly blocked by miR-483 mimic in HAVECs ( Figure 2C and 2D), further validating that the reduction of miR-483 by d-flow leads to derepression of UBE2C expression. Similar results were observed in static conditions ( Figure VG and VH in the online-only Data Supplement). Moreover, miR-483 was previously shown to directly bind to the 3′-UTR of UBE2C.
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UBE2C Regulates D-Flow-Dependent and miR-483-Dependent Inflammation and EndMT in HAVECs
We next tested whether UBE2C mediates endothelial inflammation and EndMT by treating HAVECs with UBE2C siRNA (siUBE2C), anti-miR-483, or a combination of both. SiRNA-mediated knockdown of UBE2C inhibited endothelial inflammation in static basal condition as well as in response to anti-miR-483 (to increase UBE2C expression; Figure 2E and 2F). This result suggests that UBE2C mediates the endothelial inflammation induced by the loss of miR-483. We also found that overexpression of UBE2C using the plasmids dose dependently increased monocyte adhesion in HAVECs ( Figure 2G ), further supporting our hypothesis that UBE2C induces proinflammatory responses in HAVECs.
Furthermore, we tested if d-flow-induced proinflammatory and pro-EndMT responses could be reverted by knockdown of UBE2C using siUBE2C. UBE2C knockdown prevented d-flow-induced monocyte adhesion and induction of the proinflammatory markers (VCAM1 and ICAM1) without affecting KLF2 or ASH2L expression in HAVECs ( Figure 2H and 2I). Moreover, siUBE2C treatment significantly reduced several markers of EndMT (TWIST1, TAGLN, and SLUG; Figure 2J ). In addition, siUBE2C decreased cell proliferation, but not cell migration in HAVECs ( Figure 
UBE2C Mediates Flow-Sensitive Expression of pVHL and HIF-1α
Here, we hypothesized that the increase in UBE2C (because of the loss of miR-483 under the d-flow condition) leads to ubiquitination and degradation of pVHL, which in turn increases HIF-1α levels, leading to increased expression of its target genes, endothelial inflammation, and EndMT ( Figure 3A) . First, we found that the expression of pVHL and HIF-1α was highly flow sensitive, but inversely regulated in HAVECs. Under s-flow exposure for 72 hours, expression of pVHL was high, whereas HIF-1α expression was undetectable. In contrast, under d-flow, pVHL was low whereas HIF-1α was high at the protein and mRNA levels ( Figure 3B Next, we tested whether the flow-dependent changes in expression of UBE2C, pVHL, and HIF-1α observed in HAVECs in vitro also occur in diseased human AV leaflets. We hypothesized that those molecules such as UBE2C, HIF-1α, and markers of inflammation, EndMT, and calcification are overexpressed in the fibrosa side exposed to d-flow. To this end, we performed immunohistochemical staining study using human AV tissue samples obtained from patients who underwent AV repair surgery as described in the Method and as previously reported by us. 44 UBE2C and HIF-1α expression was significantly higher in the fibrosa side of the human AV leaflets, whereas pVHL expression was higher in the ventricularis side ( Figure 3I and 3J) . Furthermore, markers of inflammation (VCAM1), EndMT (TWIST1), and calcification (RUNX2; Figure 3I and 3J) were highly expressed in the fibrosa side demonstrating side-dependent expression of pro-CAVD markers. As a control, endothelial marker CD31 was used to show intact endothelial layers in these AVs ( Figure IXA 
UBE2C Binds and Ubiquitinates pVHL, Leading to Its Degradation
We next examined how UBE2C regulates pVHL expression. Although UBE2C is a member of APC/C complex, which is known to bind and ubiquitinate pVHL for proteasomal degradation, 43 it was unknown whether UBE2C can mediate pVHL ubiquitination. Therefore, we tested whether UBE2C mediates pVHL expression in an ubiquitination-dependent manner. To this end, HAVECs were transfected with siUBE2C, and ubiquitinated proteins were pulled down and Western blotted using a pVHL antibody. We found that knockdown of UBE2C decreased ubiquitinated pVHL levels in the immunoprecipitates ( Figure 4A ). This result was independently validated A, B , UBE2C expression was increased in HAVECs exposed to DF compared with SF for 24 h, as determined by Western blot and its quantification by ImageJ (n=3). C, D, HAVECs treated with miR-483-mimic (483-M) or control mimic (Ctrl-M) followed by DF were analyzed by UBE2C Western blot and its quantification (n=3). E-G, HAVECs were cotransfected with siUBE2C or siCtrl and anti-miR-483 (AM-483) or anti-miR-control (AM-Ctrl), followed by monocyte adhesion (n=11; E) and qPCR analysis for inflammatory markers (n=3; F) . G, HAVECs transfected with UBE2C overexpression plasmid or GFP plasmid were used for monocyte adhesion assay (n=6). H, I, HAVECs treated with siUBE2C or siRNA control (SiCtrl) for 24 h, followed by DF or SF conditions for another 24 h. Then, monocyte adhesion (H) and qPCR analyses for markers of inflammation (I) and EndMT (J) were performed, normalized to 18S (n=4-6). Mean±SEM, *P<0.05. ICAM1 indicates intercellular adhesion molecule; and VCAM1, vascular cell adhesion molecule 1.
by immunoprecipitating pVHL first, followed by ubiquitin Western blotting, demonstrating that ubiquitination of pVHL was reduced when UBE2C was knocked down in HAVECs ( Figure 4B ). As expected, levels of pVHL in these cell lysates were increased ( Figure XA and XB in the online-only Data Supplement).
Because UBE2C has never been shown to bind and ubiquitinate pVHL, we tested whether they associate with each other by cotransfecting HEK cells with plasmids overexpressing UBE2C or RFP as a control and HA-pVHL-WT or HA-pVHL-RRR mutant. The HA-pVHL-RRR mutant has its 3 Lys ubiquitination sites (K159, K171, and K196) modified to Arg so that they cannot be ubiquitinated. 51 , 52 We used HA-tag antibody to immunoprecipitate HA-pVHL-WT and HA-pVHL-RRR ( Figure 4C ). UBE2C coimmunoprecipitated with either HA-pVHL-WT or HA-pVHL-RRR ( Figure 4C and Figure XC in the onlineonly Data Supplement). Interestingly, the pVHL Western blot of HA-pVHL immunoprecipitates showed bands at ≈28, 34, 55, and 80 kDa, potentially representing polyubiquitinated pVHLs in a manner dependent on UBE2C and pVHL-ubiquitination sites ( Figure 4C) . Furthermore, the Western blot using the ubiquitin antibody for the HA-pVHL immunoprecipitates showed ubiquitinated proteins at ≈35, 40, 85, and 100 kDa in a manner dependent on UBE2C and pVHL-ubiquitination sites ( Figure XD in the online-only Data Supplement).
Next, we tested whether UBE2C regulates pVHL levels in a ubiquitination-dependent manner by cotransfecting HEK cells with plasmids overexpressing UBE2C or Figure 3 . UBE2C mediates shear-dependent expression of pVHL and HIF-1α in human aortic valve endothelial cells (HAVECs), and UBE2C, pVHL, and HIF1α are expressed in a side-dependent manner in human aortic valve (AV) leaflets. A, Depicts a hypothesis that overexpression of UBE2C ubiquitinates pVHL, leading to increased HIF-1α level, endothelial inflammation, and endothelial-mesenchymal-transition (EndMT). B, HAVECs sheared for 72 h by stable flow (SF) or disturbed flow (DF) were immunostained with antibodies for pVHL or HIF-1α (B) and quantification of the image was done using ImageJ (C), or by qPCR (D) normalized to 18S (n=3-4). E, HAVECs treated with siCtrl or siUBE2C for 24 h, followed by exposure to DF for 24 h, were analyzed by Western blot (E) and Image J quantification (F) for pVHL (n=5). For the HIF-1α study, HAVECs exposed to DF for 72 h were immunostained with HIF-1α (G) and Image J quantified (H; n=6). I, Human AVs with sclerosis were stained with antibodies to UBE2C, pVHL, HIF-1α, Twist1, and Runx2 (runt-related transcription factor 2) with DAPI nuclear staining and (J) show quantification of the fluorescent intensities of each staining in the endothelial layer on each side using Image J (n=5-8). Mean±SEM, *P<0.05. Fib indicates fibrosa; and Ven, ventricularis.
RFP control and HA-pVHL WT or mutants. Four different HA-pVHL double or triple mutants on the 3 Lys ubiquitination sites were used (RRR, KRR, RKR, and RRK) in comparison to WT. 51, 52 Expression of pVHL-WT and the 3 pVHL double mutants, but not the RRR triple mutant, was decreased as UBE2C expression increased in a dosedependent manner (Figure 4D through 4G ; Figure XI in the online-only Data Supplement). This result clearly demonstrates that pVHL degradation is UBE2C dependent and it requires at least 1 of the 3 Lys ubiquitination sites. These results also demonstrate that UBE2C binds to pVHL and mediates its degradation by the ubiquitination-dependent manner.
pVHL and HIF-1α Mediate UBE2C-Dependent Inflammation and EndMT in HAVECs
We tested whether pVHL and HIF-1α regulate endothelial inflammation and EndMT by using sipVHL or siHIF1α in HAVECs. Knockdown of pVHL increased monocyte adhesion ( Figure 5A ) as well as markers of inflammation and EndMT ( Figure 5B ). We also found that knockdown of pVHL did not affect HIF1α mRNA levels. This was expected ( Figure 5B ) as pVHL is known to regulate HIF-1α protein levels via ubiquitination and proteasome degradation. 38, 56 In contrast, knockdown of HIF-1α inhibited monocyte adhesion ( Figure 5C ) and markers of inflammation and EndMT, while not affecting pVHL levels ( Figure 5D ). We then tested whether UBE2C-induced endothelial inflammation and EndMT is mediated by either pVHL or HIF1α, using siUBE2C, sipVHL, or siHIF1α in combination. Knockdown of both, UBE2C and pVHL, induced endothelial inflammation and EndMT ( Figure 5E and 5F). In contrast, silencing of both, UBE2C and HIF1α, inhibited inflammation and EndMT ( Figure 5E and 5F). These results suggest that endothelial inflammation and EndMT, induced by UBE2C, is mediated by pVHL and HIF-1α in HAVECs. and HA-pVHL-WT or HA-pVHL-RRR mutant plasmids (0.5 μg) for 48 h were immunoprecipitated using the antibody to HA-tag and Western blotted with the antibody to UBE2C or pVHL (exposed using high-and low-intensity chemiluminescence amplifications). Untreated (Unt) HEK cells were used as a control. D-G, HEK cells cotransfected with HA-pVHL-WT or HA-pVHL-RRR mutant plasmids and increasing doses of UBE2C (0.5-2 μg) or RFP plasmids for 48 h were lysed and Western blotted with antibodies to pVHL and β-actin as an internal control (D, F), and ImageJ quantified (E, G; n=3-6). Mean±SEM, *P<0.05.
MiR-483 Mimic and HIF-1α Chemical Inhibitor PX478 Inhibit Calcification in PAVs
Next, we tested whether the flow-dependent miR-483, UBE2C, pVHL, and HIF-1α pathway plays a significant role in CAVD. To this end, miR-483 mimic and the HIF-1α inhibitor PX478 were selected as treatments. We cultured freshly obtained healthy PAV leaflets in osteogenic media 47 reported using the same ex vivo flow device, 23 fibrosa flow increased AV calcification by 52% above that of the ventricularis flow. Moreover, treatment of PAV leaflets with PX478 under the fibrosa-flow condition significantly inhibited AV calcification to the level of the ventricularis flow ( Figure 6J ). These results demonstrate the therapeutic potential of targeting miR-483 and the HIF-1α pathway in treatment of CAVD.
Discussion
The main findings of our study are that miR-483 is a novel flowsensitive and side-dependent miRNA that regulates endothelial inflammation and EndMT by targeting UBE2C, which in turn regulates pVHL and HIF-1α under normal atmospheric conditions, ultimately leading to AV calcification. We also found that miR-483 mimic as well as the HIF-1α inhibitor PX478 effectively reduced AV calcification of PAVs ex vivo.
We found that miR-483 expression is increased by s-flow and in the ventricularis side which is exposed to s-flow, while decreased by d-flow and in the fibrosa side which is exposed to d-flow. Most flow experiments performed in this study used the simplified s-flow and d-flow conditions for technical reasons to represent the more complex in vivo ventricularis and . AV leaflets were then divided for total RNA isolation and qPCR assay for miR-483 (A; n=3), immunohistochemical assay using Alizarin Red (B, C; n=6) and antibodies for UBE2C, pVHL, and HIF-1α (E, F; n=6-12) and Arsenazo calcium assay (D; n=5-6). Alizarin images were quantified using MATLAB (C, H), whereas the fluorescence images (E) were quantified by ImageJ (n=3-12). J, Porcine AV leaflets were exposed to fibrosa-flow (Fib.) or ventricularis-flow (Ven.) profiles in osteogenic media for 7 days with PX478 (20 μmol/L) or vehicle. Total calcium was quantified via Arsenazo assay and normalized to dry tissue weight (n=13-15). Mean±SEM, *P<0.05. fibrosa flow profiles, respectively (Figure XIVA in the onlineonly Data Supplement). However, to validate whether the simplified s-flow and d-flow induced EC responses similar to that in response to the more complex flow profiles, we improved our flow application method and performed additional studies by exposing HAVECs to the more complex, in vivo ventricularis and fibrosa flow profiles. As shown in Figure XIV in the online-only Data Supplement, the stable ventricularis flow aligned HAVECs, upregulated KLF2 and miR-483, and downregulated UBE2C, ICAM1 (intercellular adhesion molecule), and IL6 as shown in response to s-flow (Figures 1 and  2 ; Figures V and XV) . This supports that HAVECs respond similarly to both the simplified flow conditions and the more realistic complex flow conditions tested. Therefore, we continued to use simplified s-flow and d-flow conditions for the rest of the studies for the technical convenience.
Our results demonstrated that miR-483 potently regulates endothelial function by protecting against inflammation, proliferation, and EndMT. The role of miR-483 was reported mostly in cancer cells where it regulates proliferation 57, 58 and apoptosis 57, 59, 60 ; however, the role of miR-483 is still unclear in the cardiovascular system. Recent data showed that miR-483 mediates EndMT by targeting connective tissue growth factor in human umbilical vein ECs. 29 Angiotensin II was shown to inhibit expression of miR-483 targeting the renin-angiotensin system genes in smooth muscles and heart. 30 These genes including connective tissue growth factor, however, were not flow sensitive in our gene array study using HAVECs and PAVs 23, 27 ; therefore, we did not study them. MiR-483 is located in the intronic region of IGF2 (insulin-like growth factor 2), and it was shown to be mediated by KLF4. 29 Similarly, we found that expression of miR-483 and IGF2 was mediated in a KLF2-dependent manner in HAVECs ( Figure XV in the online-only Data Supplement).
We have identified UBE2C as a flow-sensitive target of miR-483 through our in silico and validation studies. UBE2C is a member of the APC/C complex and is known to catalyze the initial monoubiquitination of protein substrates such as cyclins. [61] [62] [63] Once cyclins are monoubiquitinated, another E2 ligase, Ube2s, then elongates the ubiquitin chain (polyubiquitination) leading to their proteasomal degradation. 64, 65 Interestingly, pVHL is another well-known substrate of both APC/C 43 and Ube2s, 66, 67 but it was unknown whether UBE2C regulates pVHL ubiquitination. In addition, d-flow was shown to stabilize HIF-1α expression under normal atmospheric conditions in vascular ECs by activating NF-κB and inducing expression of the deubiquitinating enzyme Cezanne 42 ; however, it was unknown whether pVHL, a well-known HIF-1α regulator, [38] [39] [40] [41] is regulated by flow and regulates HIF-1α expression under flow conditions. We found that pVHL is highly flow sensitive, losing its expression in d-flow in HAVECs and in the fibrosa side exposed to d-flow in a UBE2C-dependent manner. Conversely, d-flow increased HIF1α expression in a UBE2C-dependent manner in HAVECs and in the fibrosa Figure 7 . Flow regulates aortic valve (AV) calcification by controlling the pVHL and HIF1α pathway via miR-483 and UBE2C. The miR-483 expression is reduced in the fibrosa endothelium in response to d-flow. The decrease in miR-483 leads to overexpression of UBE2C, which ubiquitinates and degrades pVHL. The loss of pVHL then leads to stabilization of HIF1α and induction of HIF1α target genes, which in turn induce endothelial inflammation, EndMT, and eventual AV calcification. In contrast, miR-483 expression is increased in the ventricularis endothelium exposed to s-flow, leading to a decrease in UBE2C levels. This leads to an increase in pVHL, which ubiquitinates and degrades HIF1α, leading to inhibition of HIF1α target gene expression, and subsequent prevention of endothelial inflammation, EndMT, and AV calcification. d-flow indicates disturbed flow; EndMT, endothelial-mesenchymal-transition; HIF-1α, hypoxia-inducible factor-1α; miR-483, microRNA-483-3p; pVHL, von Hippel-Lindau protein; s-flow, stable flow; and UBE2C, ubiquitin E2 ligase-C.
side. These findings suggest that UBE2C regulates pVHL and HIF-1α expression in HAVECs. Although there is an increase in HIF-1α expression under d-flow condition, it is interesting to note that siRNA-mediated knockdown of UBE2C is able to significantly reduce the HIF-1α expression by post-translational pVHL-mediated degradation preventing the downstream HIF-1α signaling cascade.
Mechanistically, we found that UBE2C targets pVHL by binding and mediating its degradation in a ubiquitinationdependent manner. Further, our data using the pVHL ubiquitination site mutants indicate that binding of UBE2C to pVHL is independent of the ubiquitination sites on pVHL; however, the UBE2C-dependent degradation of pVHL requires at least one of its ubiquitination sites. The degradation of pVHL further led to increased stabilization of HIF-1α, which in turn induced endothelial inflammation, EndMT, and AV calcification ( Figure 7) .
To our knowledge, this is the first report showing that UBE2C and pVHL are flow-sensitive proteins and play a role in endothelial inflammation and EndMT. We also found that HIF-1α is also flow sensitive and is a potent proinflammatory and pro-EndMT protein in HAVECs. Using the combination of UBE2C, pVHL, and HIF-1α siRNAs, we found that pVHL and HIF-1α mediate the UBE2C-dependent inflammation and EndMT.
Currently, the only treatment option for CAVD patients is AV replacement or repair and there are no effective medical therapies. Therefore, there is an urgent need for developing CAVD therapies. 68 Our study demonstrates that miR-483 and HIF-1α pathway are potential therapeutic targets for CAVD. Treatment with the miR-483 mimic or the HIF-1α inhibitor PX478 significantly reduced calcification of PAVs in both static and the fibrosa-flow conditions demonstrating their potential as novel anti-CAVD therapeutics. Notably, numerous clinical trials are underway using various HIF-1α inhibitors for cancer treatments. [69] [70] [71] Our study with PX478 demonstrates the potential of repurposing some of these FDA-approved HIF-1α drugs to prevent and treat CAVD. Given our findings, it may be interesting to monitor those patients treated with HIF-1α inhibitors for CAVD and atherosclerosis.
Although our current in vitro studies focused mostly on studying the effect of flow on AV endothelial cells, it is important to note that the expression of UBE2C, pVHL, HIF-1α and markers of inflammation, EndMT, and AV calcification is regulated in a side-dependent manner in vivo as we observed in the human AV tissues. These findings suggest that the miR-483-dependent UBE2C/pVHL/HIF-1α pathway established based on the in vitro studies is relevant under in vivo conditions as well, where AVs are exposed to multiple mechanical forces such as pressure and stretch in addition to flow. A limitation of our ex vivo therapeutic studies is that our treatment using the miR-483 mimic or PX478 is not delivered exclusively to the ECs but to the whole AV leaflets. 23 Therefore, the inhibitory effects of the miR-483 mimic or PX478 on AV calcification may not be solely mediated by ECs in the AV leaflets. Whether the effects of the miR-483 mimic or PX478 are mediated by VICs or other cell types in AV remain to be determined.
In conclusion, we identified a flow-sensitive and sidedependent miRNA, miR-483, which targets UBE2C in AV ECs. In turn, the aberrant expression of UBE2C leads to degradation of pVHL, which increases HIF-1α level resulting in endothelial inflammation, EndMT, and AV calcification. The miR-483 mimic and HIF-1α inhibitor are novel potential CAVD therapeutics.
